CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Revenues:	$ 0	$ 2,156	$ 3,091	$ 3,233
Costs and Expenses:
Costs of goods sold	0	613	483	1,159
Research and development	93,887	99,283	51,776	53,492
Sales and marketing	19,834	6,822	873	1,027
General and administrative	30,814	36,485	29,109	6,563
Total costs and expenses	144,535	143,203	82,241	62,241
Operating loss	(144,535)	(141,047)	(79,150)	(59,008)
Changes in fair market value of warrant liabilities	1,404	(108,636)	(61,074)	0
Warrant related expenses	0	0	(7,649)	0
Interest expense	(20,017)	(23,255)	(5,480)	(5,480)
Interest and other income	6,106	5,493	431	338
Loss on induced exchanges of debt	(897)	(13,005)	0	0
Other financing expenses	0	0	(347)	0
Insurance reimbursement	190	6,638	0	0
Foreign currency transaction gain (loss), net	0	81	23	(40)
Loss before income tax	(157,749)	(273,731)	(153,246)	(64,190)
Income tax (expense) benefit	0	(156)	(20)	5,054
Net loss	(157,749)	(273,887)	(153,266)	(59,136)
Net loss attributable to noncontrolling interest	(81)	(50)	(60)	(99)
Net loss attributable to Immunomedics, Inc. stockholders	$ (157,668)	$ (273,837)	$ (153,206)	$ (59,037)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)	$ (0.84)	$ (1.78)	$ (1.47)	$ (0.62)
Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)	188,554	153,475	104,536	94,770
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (8)	$ (105)	$ (62)	$ 1
Unrealized gain (loss) on securities available for sale	10	55	(109)	28
Other comprehensive income (loss), net of tax:	2	(50)	(171)	29
Comprehensive loss	(157,747)	(273,937)	(153,437)	(59,107)
Comprehensive loss attributable to noncontrolling interest	(81)	(50)	(60)	(99)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	(157,666)	(273,887)	(153,377)	(59,008)
Product sales
Revenues:
Revenues:	0	1,501	2,443	2,261
License fee and other revenues
Revenues:
Revenues:	0	330	284	387
Research and development
Revenues:
Revenues:	$ 0	$ 325	$ 364	$ 585